Gemini Therapeutics and Disc Medicine Announce Definitive Merger Agreement

MEI Pharma and Infinity Pharmaceuticals Announce Definitive All-Stock Merger

February 24, 2023

Pharmaceuticals

MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc. entered into a definitive merger agreement for an all-stock transaction to form a combined clinical-stage oncology company. The merged organization will advance a pipeline of three clinical-stage oncology drug candidates, including eganelisib, voruciclib, and ME-344.

Akers Biosciences and MyMD Pharmaceuticals Announce Definitive Merger Agreement

November 12, 2020

Pharmaceuticals

Akers Biosciences (NASDAQ: AKER) and MyMD Pharmaceuticals have entered into a definitive merger agreement that will combine the two companies into a single Nasdaq-listed company to be renamed MyMD Pharmaceuticals, Inc. The transaction, expected to close in H1 2021, gives current MyMD shareholders approximately 80% of the combined company and is intended to provide MyMD access to public capital and Akers' resources to accelerate development and commercialization of MyMD's immunotherapy pipeline.

GlycoMimetics to Acquire Crescent Biopharma (Merger to Operate as Crescent Biopharma, Inc.)

October 29, 2024

Healthcare Services

GlycoMimetics entered into an acquisition agreement with privately held oncology-focused biotechnology company Crescent Biopharma. The combined company will operate under the name Crescent Biopharma, Inc., advancing Crescent’s precision-engineered biologics for solid tumors, including the lead program CR-001, alongside ADC programs CR-002 and CR-003, supported by approximately $200 million in committed financing. GlycoMimetics stockholders approved the proposed merger in June 2025, and the combined company is expected to begin trading on Nasdaq on June 16, 2025 under the new ticker.

Sesen Bio and Carisma Therapeutics Announce Definitive Merger Agreement

September 21, 2022

Biotechnology

Sesen Bio, Inc. and Carisma Therapeutics Inc. have entered into a definitive merger agreement in an all-stock transaction to combine their businesses and create a well-funded, clinical-stage biotechnology company focused on engineered macrophage cell therapies for cancer and other serious disorders. The combined company is expected to trade on Nasdaq as Carisma Therapeutics Inc. under the ticker “CARM” and have approximately $180 million in cash at close, including $30 million from a concurrent financing by Carisma.

MedPharm and Tergus Pharma Merge to Create Topical & Transdermal CDMO Leader

July 8, 2024

Pharmaceuticals

MedPharm and Tergus Pharma have merged and will operate under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership of the combined company while Great Point Partners retains a significant minority stake; Michael Kane is appointed CEO and Patrick Walsh remains Executive Chairman.

biote Corp Acquires Asteria Health

January 17, 2024

Healthcare Services

biote Corp. (NASDAQ: BTMD) announced a definitive agreement to acquire F.H. Investments, Inc., doing business as Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The deal is intended to strengthen biote’s control over its supply chain through vertical integration of hormone product manufacturing and expand biote’s capabilities in 503B manufacturing and product development.